Resources

This MPS VI review considered galsulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This HT1 review considered nitisinone (only the brand Orfadin® was in scope for the review). The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This HT1 review considered nitisinone (only the brand Orfadin® was in scope for the review). The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This fact sheet describes the steps you should take in the first 24 hours following the identification of acute respiratory infections or outbreaks in residential aged care homes

We will undertake consultation in 2023 to inform the design of the new in-home aged care program. This calendar lets you know when these activities are happening.

This document contains the terms of reference for the Intellectual Disability Health Education and Training Expert Advisory Group.

This report outlines the pre-listing assessment framework and governance structure for the Prostheses List. It also addresses Ernst & Young, and Adelaide Health Technology Assessment options and recommendations.

This report provides a framework and proposes options for governance that would align the Prostheses List processes with those of other health technology assessment processes within the Government. It was developed by Adelaide Health Technology Assessment, under the Prostheses List Reform program.

This review provides options and recommendations for the future governance of the Prostheses List. It was developed by Ernst & Young under the Department’s Prostheses List Reform program.

This fact sheet provides information to help support the correct billing of Medicare Benefits Schedule Items (MBS) 18222 and 18225 for regional or field nerve blocks.

This document looks at the improvements to the National Framework for Alcohol, Tobacco and other Drug Treatment. It looks at improving processes for communication, coordination, and collaboration (CCC) between and amongst alcohol and other drug (AOD) treatment funders.

This infographic issued on 27 January 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia.

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

This Gaucher disease review considered 3 enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health.

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This Gaucher disease review considered three enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

A list of National Health and Medical Research Council (NHMRC) projects and the committed funding.

This fact sheet gives answers to common questions about the role of pharmacies and authorised persons in managing Life Saving Drugs Program (LSDP) medicines.

This presentation, delivered on 25 January 2023, contains an update to Australia's COVID-19 vaccine rollout.

This data file contains statistical data about Australia's COVID-19 vaccinations.

These reports list the percentage of people who have been vaccinated against COVID-19 by local government area (LGA).